Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer
Researchers conducted the QUADRA trial to examine if niraparib could improve outcomes in heavily pretreated patients with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 17, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Don ’ t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns
The DNA testing company, which has 10 million customers, misses nearly 90 percent of people with risky BRCA mutations. It says the criticism is overblown. (Source: NYT Health)
Source: NYT Health - April 16, 2019 Category: Consumer Health News Authors: HEATHER MURPHY Tags: Genetics and Heredity Tests (Medical) Breast Cancer DNA (Deoxyribonucleic Acid) Ovarian Cancer 23andMe Promethease (SNPedia) Invitae Corp. Source Type: news

Genetic Testing Under-Utilized in Ovarian Cancer Genetic Testing Under-Utilized in Ovarian Cancer
Only a minority of women with ovarian or breast cancer undergo recommended genetic testing, a new study suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 15, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Loss of a DNA repair system creates a unique vulnerability in many cancer types
(Broad Institute of MIT and Harvard) Cancer cells adapt to potentially fatal mutations and other molecular malfunctions by adjusting one or more other genes' activity, in the process becoming dependent on those genes for their survival and growth. The resulting genetic dependencies may provide targets for developing new precision-guided drugs or other cancer treatment strategies.Reporting in Nature, researchers describe one such vulnerability shared by a large subset of colon, gastric, endometrial, and ovarian cancer cell lines. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2019 Category: Cancer & Oncology Source Type: news

Genetic Testing Underused in Breast, Ovarian Cancer
TUESDAY, April 9, 2019 -- Only one-quarter of those with breast cancer and one-third with ovarian cancer undergo genetic testing, according to a study published online April 9 in the Journal of Clinical Oncology. Allison W. Kurian, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2019 Category: Pharmaceuticals Source Type: news

Ovarian cancer patients undertested for mutations that could guide clinical care
(Stanford Medicine) Fewer than a quarter of breast cancer patients and a third of ovarian cancer patients diagnosed between 2013 and 2014 in two states underwent genetic testing for cancer-associated mutations, according to a study by researchers at the Stanford University School of Medicine and several other organizations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2019 Category: Cancer & Oncology Source Type: news

Teenager who thought her bloating was due to junk food was diagnosed with ovarian CANCER at 19
Seren Hughes, now 23, of Flintshire, had just started university when symptoms first appeared. But thinking she was simply run down, she upped her gym routine and cut back on unhealthy food. (Source: the Mail online | Health)
Source: the Mail online | Health - April 8, 2019 Category: Consumer Health News Source Type: news

3 ways cinematic rendering helps visualize the spleen
Cinematic rendering allowed radiologists from Johns Hopkins University to uncover...Read more on AuntMinnie.comRelated Reading: Cinematic rendering makes strides in cancer evaluation Cinematic rendering paves way for 'virtual' physical exam Cinematic rendering enhances pelvic CT bone evaluation Cinematic rendering enhances ovarian cancer evaluation Cinematic rendering sheds light on abdominal pathology (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 8, 2019 Category: Radiology Source Type: news

Study: The Pill May Protect Against Ovarian Cancer
After adjusting for such factors as age and whether women had ever given birth, any use of birth control pills was associated with a 46% lower risk of death within a year of an ovarian cancer diagnosis, the study found. (Source: WebMD Health)
Source: WebMD Health - April 3, 2019 Category: Consumer Health News Source Type: news

Cancer survivor who had an OVARY removed defies the odds to give birth to a healthy boy
Amy Smith-Morris, from Saskatoon in Canada, was diagnosed with ovarian cancer in 2016 after returning from her honeymoon but gave birth to her first child, Max, in March this year. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2019 Category: Consumer Health News Source Type: news

Birth Control Pills May Protect Against Most Serious Ovarian Cancer: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 3, 2019 Category: Cancer & Oncology Tags: Gynecology, Obstetrics, Oncology, News, Source Type: news

Birth Control Pills May Protect Against Most Serious Ovarian Cancer: Study
WEDNESDAY, April 3, 2019 -- The protection that birth control pills offer against ovarian cancer is strongest with the most aggressive forms of the disease, a new study says. For several years, researchers have noted that women who have used oral... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 3, 2019 Category: General Medicine Source Type: news

Birth Control Pills May Protect Against Most Serious Ovarian Cancer: Study
Title: Birth Control Pills May Protect Against Most Serious Ovarian Cancer: StudyCategory: Health NewsCreated: 4/3/2019 12:00:00 AMLast Editorial Review: 4/3/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 3, 2019 Category: Cancer & Oncology Source Type: news

Birth Control Pills May Protect Against Most Serious Ovarian Cancer: Study
(Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - April 3, 2019 Category: Cancer & Oncology Source Type: news

New role for a driver of metastatic cancers
(Salk Institute) Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute researchers have revealed a new role for the CDK12 protein. The findings were published in the print version of Genes& Development on April 1, 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

Women Die From Heart Attacks More Often Than Men. Here ’s Why — and What Doctors Are Doing About It
Lilly Rocha was 37 years old in 2008 when she began having strange symptoms. When people asked her questions, she knew the answers but couldn’t articulate them. A tingling sensation on her left breast became painful. She thought she might have breast cancer, but her doctor assured her she was just experiencing stress from her demanding job. Her symptoms continued to get worse, and doctors continued to dismiss her. Three months later, at work, she became seriously ill. Luckily, her boss recognized the symptoms—chest and jaw pain and numbness in her left hand—and drove her to the nearest emergency room, whe...
Source: TIME: Health - April 1, 2019 Category: Consumer Health News Authors: Barbara Sadick Tags: Uncategorized heart health Source Type: news

Cinematic rendering makes strides in cancer evaluation
Cinematic rendering proved to be as accurate as conventional volume rendering...Read more on AuntMinnie.comRelated Reading: Cinematic rendering paves way for 'virtual' physical exam Cinematic rendering enhances pelvic CT bone evaluation Cinematic rendering enhances ovarian cancer evaluation Physicians prefer cinematic rendering for ankle injuries Cinematic rendering sheds light on abdominal pathology (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 1, 2019 Category: Radiology Source Type: news

Niraparib not cost  effective for platinum-sensitive ovarian cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2019 Category: Drugs & Pharmacology Source Type: news

Landmark Trial Halts Aggressive Surgery in Ovarian Cancer Landmark Trial Halts Aggressive Surgery in Ovarian Cancer
Maurie Markman discusses recent results from a phase 3 randomized trial of lymphadenectomy in advanced ovarian cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Stand up to Cancer funded research to be presented March 30-April 3 at AACR Annual Meeting
(Stand Up To Cancer) Stand Up To Cancer supported research immunotherapy; organoids, precision therapies and cancer interception; pancreatic, breast, ovarian, lung, brain, colorectal, and pediatric cancers will be presented by SU2C-affiliated researchers including Nobel laureate James P Allison, PhD; Elizabeth Jaffee, MD, Crystal L. Mackall, MD, E John Wherry, PhD, Peter Dirks, MD, PhD, among others. SU2C SAC vice chair Raymond DuBois, MD to be honored. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 27, 2019 Category: Cancer & Oncology Source Type: news

Mother of two reveals she planned her wedding and funeral after being diagnosed with ovarian cancer 
EXCLUSIVE: Tina Potts, 40, from Wicklow Town, Ireland, has battled terminal cancer for 18 months. She married her partner of 13 years on Friday to 'make memories' for her two children. (Source: the Mail online | Health)
Source: the Mail online | Health - March 26, 2019 Category: Consumer Health News Source Type: news

Surgery to Reduce Ovarian Cancer Risk — One Step or Two? Surgery to Reduce Ovarian Cancer Risk — One Step or Two?
Results from TUBA and WISP show high-risk women have few remaining cancer worries or decision regrets after undergoing prophylactic surgery to reduce ovarian cancer risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Racial Disparities in Hospice Enrollment Persist in Ovarian Cancer
In this study, researchers aimed to further characterize differences in hospice use in a cohort of ovarian cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - March 25, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Niraparib Extends Time Without Symptoms in Ovarian Cancer
Findings based on phase 3 study of maintenance therapy with PARP inhibitor following treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 22, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Novocure launches pivotal ovarian cancer trial
Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian cancer. The 540-patient trial has a primary endpoint of overall survival, with secondary endpoints that include progression-free survival, objective response rate, severity and frequency of adverse events and quality of life. Get the full story at our sister site, Drug Delivery Business News. The post Novocure launches pivotal ovarian cancer trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 22, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Niraparib Extends Time Without Symptoms in Ovarian Cancer
FRIDAY, March 22, 2019 -- Women with recurrent ovarian cancer who receive the poly ADP ribose polymerase (PARP) inhibitor niraparib as maintenance therapy after treatment have both more time without side effects and significantly longer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 22, 2019 Category: Pharmaceuticals Source Type: news

Nigeria: Talcum Powder May Cause Cancer, Experts Warn
[Guardian] Researchers are unanimous that talc or talcum powder can cause lung, ovarian, stomach and endometrial (uterine) cancers. They said talc consisting of asbestos is generally accepted as being able to cause cancer if it is inhaled or/and used regularly in the genital area. Evidence on asbestos-free talc is however less clear. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 22, 2019 Category: African Health Source Type: news

SGO 2019: TWiST Backs Benefits of PARP Inhibitor in Ovarian Cancer
The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer, but Safety Questioned
The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising, but with some caveats. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer
The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Women's Wellness: Connect with women living with gynecologic cancer
Gynecologic cancers include?cervical cancer, endometriosis, fibroids,?ovarian cancer, pelvic masses,?uterine cancer,?vaginal cancer?and?vulvar cancer. Mayo Clinic Connect is a place where you can meet women living with a gynecologic cancer or caring for someone with gynecologic cancer. You can ask your questions, share your story, or just say hello. "Connect members find connection, support, and information from [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2019 Category: Databases & Libraries Source Type: news

Vaccine Boosts OS in Late-Stage, Relapsed Ovarian Cancer
(MedPage Today) -- Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - March 20, 2019 Category: OBGYN Source Type: news

SGO 2019: Dendritic Cell –Based Immunotherapy Shows “Dramatic” Response for Ovarian Cancer
The phase II trial evaluated  dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

' End of the Road' for Trabectedin in Ovarian Cancer?
(MedPage Today) -- Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 19, 2019 Category: Hematology Source Type: news

Mother, 38, claims she saw doctors over 20 TIMES before an ovarian cancer diagnosis
Claire Thompson visited her GP and A&E around 20 times over 18 months with severe heavy bleeding, She underwent a life-saving hysterectomy in 2016 when doctors discovered cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - March 19, 2019 Category: Consumer Health News Source Type: news

New class of drugs could treat ovarian cancer
(University of Manchester) A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing. The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer Cell, showed that the drugs, called PARG inhibitors, can kill ovarian cancer cells by targeting weaknesses within their ability to copy their DNA. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: news

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer
Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Lymphadenectomy in Advanced Ovarian Cancer: Will It Improve Survival?
A randomized trial tested whether lymphadenectomy would improve survival outcomes in patients with advanced ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

When PARP Inhibitors Fail in Ovarian Cancer
(MedPage Today) -- Study identifies subgroup for whom another go could be worthwhile (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 18, 2019 Category: Hematology Source Type: news

TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer
New analysis of the NOVA trial confirms clinical benefit from niraparib for patients with recurrent ovarian cancer. The benefit occurred both in patients with and in those without BRCA mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Enzyme USP15 may have potential role in future treatment of various cancers
(George Washington University) A team at the George Washington University Cancer Center found that the deubiquitinating enzyme USP15 is a potential biomarker for treatments of pancreatic cancer, as well as ovarian and breast cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 15, 2019 Category: International Medicine & Public Health Source Type: news

How to catch ovarian cancer earlier
(American Society for Biochemistry and Molecular Biology) Ovarian cancer is often diagnosed too late for effective treatment. Israeli researchers are announcing a liquid biopsy-based diagnostic protocol for ovarian cancer, with higher sensitivity than previous approaches, that may help women in high-risk populations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2019 Category: Cancer & Oncology Source Type: news

Infertility in Women Linked to Modestly Elevated Cancer Risk
Overall risk higher for developing cancer; increased risks seen for uterine, ovarian, lung, thyroid cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 15, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Oncology, Journal, Source Type: news

Medical News Today: Ovarian cancer: New drug may prevent recurrence
New research in mice identifies a compound that significantly improves ovarian cancer survival by targeting stem-like cancer cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

California Jury Awards $29 Million to Woman Who Says She Got Cancer from Johnson & Johnson Baby Powder
A woman who claims asbestos in Johnson & Johnson products caused her deadly cancer was awarded $29.4 million by a California jury on Wednesday, Reuters reports. A jury in a California Superior Court in Oakland determined that defective Baby Powder was a “substantial contributing factor” to Terry Leavitt’s mesothelioma, an aggressive cancer that affects the tissue that coats internal organs, the Associated Press reports. Leavitt said she often used two talcum-powder-based Johnson & Johnson products — Baby Powder and Shower to Shower powder — in the 1960s and 1970s, and claims they contr...
Source: TIME: Health - March 14, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer onetime Source Type: news

Woman, 25, who complained of abdominal pain for nine years diagnosed with ovarian cancer
Amanda Kabbabe, 25, from Hoboken, New Jersey, was diagnosed with ovarian cancer in November 2017 after complaining of sharp stomach pains to doctors for nine years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2019 Category: Consumer Health News Source Type: news

Woman, 26, who complained of abdominal pain for nine years diagnosed with ovarian cancer
Amanda Kabbabe, 26, from Hoboken, New Jersey, was diagnosed with ovarian cancer in November 2017 after complaining of sharp stomach pains to doctors for nine years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2019 Category: Consumer Health News Source Type: news

Ovarian cancer patient, 25, learns she can't have children due to emergency hysterectomy
Shaylee Bedward, 25, from Bloomington, Indiana, was diagnosed with stage 3 ovarian cancer in October 2017. After chemotherapy didn't work, she underwent a hysterectomy. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2019 Category: Consumer Health News Source Type: news

Fertility issues raise the risk of cancer in women
A study has found that women with fertility problems are 18 per cent more likely to get cancer, in particular womb and ovarian cancers. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2019 Category: Consumer Health News Source Type: news

Talc cancer concerns get their day in Congress
The son of a woman who was a "true fan" of Johnson& Johnson's Baby Powder, who made it a "necessary part of our hygienic routine," testified before lawmakers on Tuesday, asking for help for women like his mother, who died of ovarian cancer after regularly using talc-based powder. (Source: CNN.com - Health)
Source: CNN.com - Health - March 12, 2019 Category: Consumer Health News Source Type: news